The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater.
 
Pat Gulhati
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
No Relationships to Disclose
 
Rachna T. Shroff
Stock and Other Ownership Interests - Celgene
Consulting or Advisory Role - Celgene; Clovis Oncology
Research Funding - Celgene; Lilly
Travel, Accommodations, Expenses - Celgene; Clovis Oncology
 
Gauri R. Varadhachary
No Relationships to Disclose
 
Scott Kopetz
Consulting or Advisory Role - Agendia; Amgen; Array BioPharma; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merrimack; Roche; Sanofi; Sysmex; Taiho Pharmaceutical
Research Funding - Agendia; Amgen; Biocartis; GlaxoSmithKline; Guardant Health; Roche; Sanofi; Sysmex
 
Milind M. Javle
No Relationships to Disclose
 
Wei Qiao
No Relationships to Disclose
 
Huamin Wang
No Relationships to Disclose
 
Jeffrey Morris
No Relationships to Disclose
 
Robert A. Wolff
No Relationships to Disclose
 
Michael J. Overman
Research Funding - Roche/Genentech